http://ADPHARMA.NET
ADPHARMACEUTICALS1 5847dbd200671109b8397d6c False 301 20
OK
background image not found
Found results for
'official clinical trials'
Hepcinat - LP INR   0 INR  0
-NaN%

Hepcinat - LP

We are pioneer supplier of Hepcinat to Russia. HEPCINAT-LP contains polymerase inhibitors which called sofosbuvir and ledipasvir . Hepcinat-LP manufactured by Natco Pharma and approved for treatment of patients infected with Hepatitis C (HCV genotypes 1 and 4). Sofosbuvir & Ledipasvir is FDA-approved and EASL recommended treatment protocol for HCV, which does not include interferon or ribavirin. The clinical trials have proven very high success rate of sofosbuvir in combination with ledipasvir. Hepcinat-LP Tablets is a formulation combination of anti-viral medications Ledipasvir and Sofosbuvir used in the treatment of Chronic Hepatitis C Virus (CHCV) infection genotype 1. Hepcinat-LP is a prescription medicine containing Ledipasvir (90mg) a viral NS5A inhibitor and Sofosbuvir (400mg) a nucleotide inhibitor of the viral RNA polymerase. In one of official clinical trials involved more than 1,600 people with HCV genotype 1. The course of treatment was only 84 days. By the end of therapy 1556 patients achieved the primary target – absence of the virus. Adverse events that occurred in patients receiving sofosbuvir together with ledipasvir were mild and generally accompanied by headache and fatigue. Working pattern: Sofosbuvir+ledipasvir targetly affects to specific proteins involved in viral replication and thus totally stop the disease.

INR 0 INR 0

Availability:True

Pay mode:COD only

view details
Resof 400 mg INR   0 INR  0
-NaN%

Resof 400 mg

We are one of the leading exporters of Resof to Russia. Resof 400mg (Sofosbuvir) is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase - the key enzyme mediating HCV RNA replication. This triphosphate compound mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in chain termination. Resof 400mg is available as a 400 mg tablet. The recommended dose of sofosbuvir is 400 mg taken orally once daily, with or without food. The 400 mg dose of sofosbuvir should be used, regardless of the patient's genotype and prior hepatitis C treatment experience. No dose adjustment is needed for mild-to-moderate renal impairment or with mild, moderate, or severe hepatic impairment. Resof 400mg has been very well-tolerated in clinical trial. The most common adverse effects observed with sofosbuvir, when used in combination with ribavirin, have been fatigue and headache. Sofosbuvir is pregnancy category B.

INR 0 INR 0

Availability:True

Pay mode:COD only

view details
1
false